Recombinant
RabMAb

Recombinant Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (HRP) (ab200782)

Overview

  • Product name

    Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (HRP)
    See all Retinoid X Receptor alpha/RXRA primary antibodies
  • Description

    Rabbit monoclonal [EPR7106] to Retinoid X Receptor alpha/RXRA (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: WBmore details
    Unsuitable for: IHC-P
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human Retinoid X Receptor alpha/RXRA aa 1-100 (N terminal). The exact sequence is proprietary.
    Database link: P19793

  • Positive control

    • WB: MCF7, HeLa, K562, RAW 264.7, PC12 and NIH 3T3 whole cell lysates.
  • General notes

     This product was previously labelled as Retinoid X Receptor alpha

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

Properties

Applications

Our Abpromise guarantee covers the use of ab200782 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/5000. Detects a band of approximately 51 kDa (predicted molecular weight: 51 kDa).
  • Application notes
    Is unsuitable for IHC-P.
  • Target

    • Function

      Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes.
    • Tissue specificity

      Highly expressed in liver, also found in lung, kidney and heart.
    • Sequence similarities

      Belongs to the nuclear hormone receptor family. NR2 subfamily.
      Contains 1 nuclear receptor DNA-binding domain.
    • Domain

      Composed of three domains: a modulating N-terminal domain (AF1 domain), a DNA-binding domain and a C-terminal ligand-binding domain (AF2 domain).
    • Post-translational
      modifications

      Phosphorylated on serine and threonine residues mainly in the N-terminal modulating domain. Constiutively phosphorylated on Ser-21 in the presence or absence of ligand. Under stress conditions, hyperphosphorylated by activated JNK on Ser-56, Ser-70, Thr-82 and Ser-260 (By similarity). Phosphorylated on Ser-27, in vitro, by PKA. This phosphorylation is required for repression of cAMP-mediated transcriptional activity of RARA.
      Sumoylation negatively regulates transcriptional activity. Desumoylated specifically by SENP6.
    • Cellular localization

      Nucleus.
    • Information by UniProt
    • Database links

    • Alternative names

      • FLJ00280 antibody
      • FLJ00318 antibody
      • FLJ16020 antibody
      • FLJ16733 antibody
      • MGC102720 antibody
      • NR2B1 antibody
      • Nuclear receptor subfamily 2 group B member 1 antibody
      • OTTHUMP00000022510 antibody
      • Retinoic acid receptor RXR alpha antibody
      • Retinoic acid receptor RXR-alpha antibody
      • Retinoid X nuclear receptor alpha antibody
      • Retinoid X receptor alpha antibody
      • RXR alpha1 antibody
      • Rxra antibody
      • RXRA_HUMAN antibody
      • RXRalpha1 antibody
      see all

    Images

    • All lanes : Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (HRP) (ab200782) at 1/1000 dilution

      Lane 1 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate
      Lane 2 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
      Lane 3 : K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate
      Lane 4 : RAW 264.7 (Mouse leukaemic monocyte macrophage cell line) Whole Cell Lysate
      Lane 5 : PC12 (Rat adrenal pheochromocytoma cell line) Whole Cell Lysate
      Lane 6 : NIH 3T3 (Mouse embryonic fibroblast cell line) Whole Cell Lysate

      Lysates/proteins at 10 µg per lane.

      Developed using the ECL technique.

      Performed under reducing conditions.

      Predicted band size: 51 kDa
      Observed band size: 51 kDa


      Exposure time: 12 minutes


      This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab200782 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

    References

    ab200782 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab200782.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up